Aprea Therapeutics, Inc.
APRE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $18,128 | $17,003 | $548 | $61,092 |
| - Cash | $22,850 | $21,607 | $28,787 | $53,076 |
| + Debt | $0 | $0 | $0 | $190 |
| Enterprise Value | -$4,722 | -$4,604 | -$28,238 | $8,207 |
| Revenue | $1,503 | $583 | $0 | $0 |
| % Growth | 157.6% | – | – | – |
| Gross Profit | -$7,861 | $576 | -$16,402 | -$272 |
| % Margin | -523.2% | 98.8% | – | – |
| EBITDA | -$14,297 | -$14,280 | -$37,368 | -$36,856 |
| % Margin | -951.5% | -2,448.4% | – | – |
| Net Income | -$12,959 | -$14,287 | -$112,662 | -$36,537 |
| % Margin | -862.4% | -2,449.6% | – | – |
| EPS Diluted | -2.35 | -3.95 | -1,359.79 | -34.88 |
| % Growth | 40.5% | 99.7% | -3,798.5% | – |
| Operating Cash Flow | -$13,557 | -$12,178 | -$25,011 | -$37,686 |
| Capital Expenditures | -$15 | -$93 | $0 | $0 |
| Free Cash Flow | -$13,572 | -$12,271 | -$25,011 | -$37,686 |